April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Ranibizumab-induced Reduction In The Total Area Of Predominantly Classic Choroidal Neovascularization In Patients With Age-related Macular Degeneration
Author Affiliations & Notes
  • Karl G. Csaky
    Ophthalmology, Retina Foundation of the Southwest, Dallas, Texas
  • Howard Shapiro
    Genentech, Inc., San Francisco, California
  • Lisa Tuomi
    Genentech, Inc., San Francisco, California
  • Footnotes
    Commercial Relationships  Karl G. Csaky, Allergan (C), Genentech (C), Heidelberg Engineering (C), Novartis (C), Ophthotech (I), QLT (C); Howard Shapiro, Genentech, Inc. (E); Lisa Tuomi, Genentech, Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 132. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Karl G. Csaky, Howard Shapiro, Lisa Tuomi; Ranibizumab-induced Reduction In The Total Area Of Predominantly Classic Choroidal Neovascularization In Patients With Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):132.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To investigate the effect of monthly ranibizumab 0.3 mg and 0.5 mg on the total area of predominantly classic choroidal neovascularization (CNV) in patients with age-related macular degeneration enrolled in the Phase III ANCHOR trial.


Fluorescein angiograms from 280 ranibizumab-treated study eyes were graded at a central reading center. The primary outcome of interest was percent change from baseline to Month 12 for total area of CNV (CNVpct), categorized into 4 classes: (I) reduction of more than 50%, (II) reduction between 50% up to 25%, (III) reduction of 25% to increase of 25%, and (IV) increase of more than 25%.


The mean (range) area of CNV at baseline (disc areas) for the 0.3 mg and 0.5 mg ranibizumab treatment groups were 1.48 (0.11 - 6.80) vs 1.31 (0.05 - 7.50) respectively. At 3 months post-baseline a larger proportion of 0.5 mg patients vs. 0.3 mg patients fell within the CNVpct Class I (Table), though the treatment group difference among all classes was not statistically significant (p=0.11); for a dichotomous comparison of CNVpct Class I vs. all other classes, the treatment group difference trended towards statistical significance. (p=0.076). At 6, 9 and 12 months post-baseline, the percentage distributions comparing 0.3 and 0.5 mg became more similar; the dichotomous comparisons were not statistically significant (p>=0.19). From Month 3 through Month12 the representation of CNVpct Class I increased from 9.1% to 18.2% for 0.3 mg patients and from 16.7% to 22.4% for 0.5 mg patients.


This work demonstrates a trend of more potent CNV reduction with higher doses of ranibizumab in some patients. On-going research is examining correlates of vision with regression rates.  

Keywords: age-related macular degeneration • choroid: neovascularization • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.